Dr. Mitchell Goldman joined Amicus Therapeutics in January 2020 and currently serves as Chief Medical Officer. He brings over 20 years of experience in the pharmaceutical industry, spanning early development, proof-of-concept studies and medical affairs. Dr. Goldman is responsible for providing strategic and operational leadership for all Amicus Clinical Research and Safety functions, both internally to Amicus and with external stakeholders.
Prior to joining Amicus, Dr. Goldman served a long-term tenure at AstraZeneca during which he advanced through various senior and executive level roles, concluding his tenure as Vice President of Late Stage Biologics for Respiratory, Autoimmune and Anti-Infectives.
Dr. Goldman has a B.A. from the University of Colorado and earned a Ph.D. and M.D. from Case Western Reserve University. He is also an author on over 40 publications in peer-reviewed journals including Cell, Nature Genetics, Lancet, and the New England Journal of Medicine.